Bhattacharya, U.; Kamran, M.; Manai, M.; Cristofanilli, M.; Ince, T.A.
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers 2023, 15, 332.
https://doi.org/10.3390/cancers15020332
AMA Style
Bhattacharya U, Kamran M, Manai M, Cristofanilli M, Ince TA.
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers. 2023; 15(2):332.
https://doi.org/10.3390/cancers15020332
Chicago/Turabian Style
Bhattacharya, Udayan, Mohammad Kamran, Maroua Manai, Massimo Cristofanilli, and Tan A. Ince.
2023. "Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide" Cancers 15, no. 2: 332.
https://doi.org/10.3390/cancers15020332
APA Style
Bhattacharya, U., Kamran, M., Manai, M., Cristofanilli, M., & Ince, T. A.
(2023). Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers, 15(2), 332.
https://doi.org/10.3390/cancers15020332